<DOC>
	<DOCNO>NCT00014144</DOCNO>
	<brief_summary>RATIONALE : Biological therapy ZD 1839 may interfere growth tumor cell slow growth cancer urinary tract . PURPOSE : Phase II trial study effectiveness ZD 1839 treat patient advanced cancer urinary tract .</brief_summary>
	<brief_title>S0031 , ZD 1839 Treating Patients With Advanced Cancer Urinary Tract</brief_title>
	<detailed_description>OBJECTIVES : - Determine 6-month progression-free survival rate patient advance transitional cell carcinoma urothelium treat ZD 1839 . - Determine overall survival response ( confirmed complete partial response ) patient treat regimen . - Determine qualitative quantitative toxicity regimen patient . - Evaluate change growth factor protein kinase expression treatment time disease progression patient treat regimen . OUTLINE : Patients receive oral ZD 1839 daily . Treatment continue absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year every 6 month 2 year . PROJECTED ACCRUAL : A total 30-55 patient accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell carcinoma ( TCC ) urothelium ( bladder , renal pelvis , ureter , urethra ) curable surgery radiotherapy Any T , N03 , M1 unresectable M0 Poorly differentiate TCC , predominant TCC rare foci squamous differentiation , rare focus adenocarcinoma allow Measurable disease At least 1 lesion accessible biopsy Soft tissue disease irradiate within past 2 month consider measurable disease Progressive recurrent disease 1 prior systemic chemotherapy regimen advance disease No adenocarcinoma , small cell carcinoma , sarcoma , squamous cell carcinoma , mixed histology PATIENT CHARACTERISTICS : Age : Any age Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Platelet count least 100,000/mm3 Absolute granulocyte count least 1,200/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 2 time ULN Renal : Creatinine great 2 time ULN Other : No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer currently complete remission Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent filgrastim ( GCSF ) Chemotherapy : See Disease Characteristics No prior adjuvant chemotherapy At least 28 day since prior chemotherapy recover Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 28 day since prior radiotherapy recover Surgery : See Disease Characteristics At least 28 day since prior surgery recover Other : No prior systemic therapy biopsy study entry At least 28 day since prior intravesical therapy recover No concurrent agent induce CYP3A4 ( e.g. , nafcillin , rifampin , carbamazepine , phenobarbital , phenytoin , St. John 's Wort )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>recurrent transitional cell cancer renal pelvis ureter</keyword>
	<keyword>anterior urethral cancer</keyword>
	<keyword>posterior urethral cancer</keyword>
</DOC>